We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Redx Pharma
Up to $870m KRAS deal marks third Jazz collaborationFutura Medical
Eroxon continues to build, further new launches expectedArecor Therapeutics
New deals and first royalties to aid growth; key data H124Scancell
Heading into important 2024 clinical catalystsANGLE
Building content to drive widespread adoptionArecor Therapeutics
Sanofi deal for INBRX-101 validates Arestat technologyRedx Pharma
Anticipating clinical momentum and catalysts in 2024Avacta
Tailored tumour targetting with pre|CISIONArecor Therapeutics
Second in-house Specialty Hospital dealScancell
Successful upsized placing raises over £10m